Vitamin E δ-Tocotrienol Multiple Dose in Healthy Subjects

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
BioGene Life Science
Information provided by (Responsible Party):
H. Lee Moffitt Cancer Center and Research Institute
ClinicalTrials.gov Identifier:
NCT01450046
First received: October 7, 2011
Last updated: June 12, 2014
Last verified: June 2014
  Purpose

The Principal Investigator believes that Vitamin E δ-Tocotrienol will slow the progression of pancreatic cancer cells. Therefore, the investigators must determine the safety and tolerability of Vitamin E δ-Tocotrienol in healthy participants before administering to cancer patients. The investigators will do this by giving participants a dose of up to1600 mg twice a day, not to exceed 3200 mg total for 14 consecutive days.


Condition Intervention Phase
Pancreatic Cancer
Drug: Vitamin E δ-Tocotrienol
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Vitamin E δ-Tocotrienol Following Multiple Dose Administration in Healthy Subjects

Resource links provided by NLM:


Further study details as provided by H. Lee Moffitt Cancer Center and Research Institute:

Primary Outcome Measures:
  • Number of Participants With Treatment Related Adverse Events [ Time Frame: 3 Weeks Per Participant ] [ Designated as safety issue: Yes ]
    The primary objective of this study is to evaluate the safety and tolerability of Vitamin E δ-Tocotrienol and to determine the maximum administered dose (MAD) or maximum tolerated dose (MTD) of Vitamin E δ-Tocotrienol administered twice daily for 14 days. Safety analyses and summary tables will include data collected for all subjects who receive at least one dose of study drug.


Secondary Outcome Measures:
  • Maximum Plasma Concentration (Cmax) of Vitamin E δ-Tocotrienol [ Time Frame: 3 Weeks Per Participant ] [ Designated as safety issue: No ]
    To determine the effects of dose on the plasma pharmacokinetic (PK) of Vitamin E δ-Tocotrienol following multiple dose administration in healthy subjects.

  • Pharmacodynamic (PD) Markers of Vitamin E δ-Tocotrienol Activity in Peripheral Blood [ Time Frame: Day 1, Day 8 Day 14 ] [ Designated as safety issue: No ]
    Peripheral blood mononuclear cells will be collected at each time point for examination of biomolecular markers not limited to Erk, p-Erk, AKT, p-AKT, p27, Ki-67, and exportin.


Enrollment: 18
Study Start Date: October 2011
Estimated Study Completion Date: January 2015
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Phase I Dose Escalation
Each investigator will be provided with adequate supplies of Vitamin E δ -Tocotrienol, which will be supplied as 100-mg, 200-mg, and 400-mg capsules. Vitamin E δ-Tocotrienol will be administered orally once. The dose administered to each subject will be fixed and based on cohort assignment. Doses will be administered at the clinical site during each protocol-defined visit.
Drug: Vitamin E δ-Tocotrienol
Vitamin E δ-Tocotrienol will be administered orally as a single agent twice daily for 14 consecutive days. Vitamin E δ-Tocotrienol is supplied as 100-mg, 200-mg, and 400-mg capsules. The first cohort will be dosed with δ-tocotrienol at 100 mg twice daily for 14 consecutive days. A minimum of 3 subjects is planned for each dosing cohort with Vitamin E δ-Tocotrienol dose escalation dependent on safety and available PK data from prior cohorts. At the MTD or MAD, 18 subjects will be enrolled.
Other Name: Delta-tocotrienol

Detailed Description:

Participants will be accrued in cohorts of three. The decision to dose escalate will be made by the Cohort Review Committee (CRC) based on safety after the last subject in the current cohort has completed the Study Treatment Period. The study will consist of the following procedures:

  • Pre-Treatment Period: The screening period must occur within 7 days of dosing.
  • Study Treatment Period (14 days): Vitamin E δ-Tocotrienol will be administered orally twice daily for 14 consecutive days
  • Post-Treatment Period: Subject will return to the study site 7 days after the dose of Vitamin E δ-Tocotrienol for an end-of-treatment assessment. On day 8 (± 2 days) after the last dose of study drug, the investigator will obtain follow-up information. Any serious adverse events (SAEs) present at 7 days after the last dose and possibly related to study drug will be followed until resolution, stabilization, or initiation of treatment that confounds the ability to assess the event.
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Equal to or greater than 18 years of age
  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤2
  • Adequate organ function:

    • Serum creatinine ≤1.5 mg/dL or calculated creatinine clearance ≥60 mL/min.
    • Bilirubin ≤ the intuitional upper limits of normal
    • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) to be within institutional normal range
    • Absolute neutrophil count (ANC) ≥1000mm³
    • Platelet count ≥100,000mm³
  • Has the capability of understanding the informed consent document and has signed the informed consent document
  • Sexually active participants (male and female) must use medically acceptable methods of contraception during the course of the study.
  • Women of childbearing potential must have a negative pregnancy test at screening.
  • Able to understand and comply with the requirements of the protocol

Exclusion Criteria:

  • receiving investigational therapy (other than the investigational therapy under study)
  • Have received investigational therapy within 30 days prior to first dose of study drug
  • Patients who are unable to swallow capsules
  • Patients with prior malignancies, other than squamous or basal cell carcinomas, unless disease free for ≥ 5 years
  • Have had prior major surgery within 30 days prior to first dose of study drug
  • The patient has active infection or fever >38.5C within 3 days prior to first dose of study drug.
  • Have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, hypertension, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Unable or unwilling to stop taking vitamins, herbal remedies, or nonprescription medications
  • Pregnant or breastfeeding
  • Unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01450046

Locations
United States, Florida
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States, 33612
Sponsors and Collaborators
H. Lee Moffitt Cancer Center and Research Institute
BioGene Life Science
Investigators
Principal Investigator: Amit Mahipal, M.D. H. Lee Moffitt Cancer Center and Research Institute
  More Information

Additional Information:
No publications provided

Responsible Party: H. Lee Moffitt Cancer Center and Research Institute
ClinicalTrials.gov Identifier: NCT01450046     History of Changes
Other Study ID Numbers: MCC-16153
Study First Received: October 7, 2011
Last Updated: June 12, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by H. Lee Moffitt Cancer Center and Research Institute:
pancreas
gastrointestinal
GI
prevention
vitamin E

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Vitamins
Vitamin E
Alpha-Tocopherol
Tocopherols
Tocotrienols
Micronutrients
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents

ClinicalTrials.gov processed this record on September 22, 2014